Divergent effects of infliximab and anakinra therapies on macrophage phenotype from patients with refractory rheumatoid arthritis

International Journal of Immunopathology and Pharmacology

Volumn 23, Issue 2, 2010, Pages 491-501

  Pham, T N Q ^a,c   Rahman, P ^b   Richardson, Vernon J ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b St Clare's Mercy Hospital   (Canada)

^c CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Anakinra; anti TNF ; IL 1Ra; Inducible nitric oxide synthase; Inflammation; Infliximab; Macrophage phenotype; Monocyte; Nitric oxide; NOS2; PKC ; Rheumatoid arthritis

Indexed keywords

INFLIXIMAB; INTERLEUKIN 1; METHOTREXATE; NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN KINASE C ETA; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENE EXPRESSION; HUMAN; MACROPHAGE; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SYMPTOM;

EID: 77955372160     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201002300211     Document Type: Article

References (27)

1. Arend WP. The pathophysiology and treatment of rheumatoid arthritis. Arthritis Rheum 1997; 40:595-7.
2. Schumacher HR, Kitridou RC. Synovitis of recent onset. A clinicopathologic study during the first month of disease. Arthritis Rheum 1972; 15:465-85.
3. Pham TNQ, Raman P, Richardson VJ. Role of Nitric Oxide in bone and joint physiology and patholophysiology In: Wallace AV, Richardson VJ, ed. Perspectives on NO in Physiology and Pathology. Trans World Press, 2009; p. 123-55.
4. Abramson SB, Amin AR, Clancy RM, Attur M. The role of nitric oxide in tissue destruction. Best Pract Res 2001; 15:831-45.
5. Pham TN, Rahman P, Tobin YM, Khraishi MM, Hamilton SF, Alderdice C, Richardson VJ. Elevated serum nitric oxide levels in patients with inflammatory arthritis associated with co-expression of inducible nitric oxide synthase and protein kinase C-eta in peripheral blood monocyte-derived macrophages. J Rheumatol 2003; 30:2529-34.
6. Heale CE, Fahraeus-Van Ree GE, Rahman P, Richardson VJ. Progressive and concordant expression of PKC-eta and iNOS phenotypes in monocytes from patients with rheumatoid arthritis: association with disease severity. J Histochem Cytochem 2007; 55:495-503.
7. Shanahan JC, Moreland LW, Carter RH. Upcoming biologic agents for the treatment of rheumatic diseases. Curr Opin in Rheumatol 2003; 15:226-36.
8. Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 2000; 51:207-29.
9. Calabrese LH. Anakinra treatment of patients with rheumatoid arthritis. Annal Pharmacother 2002; 36:1204-9.
10. Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, Modafferi D, Poulakos J, Sun G. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003; 48:927-34.
11. Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, Hansen RA, Morgan LC, Lohr KN. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008; 148:124-34.
12. Dinarello CA. Anti-cytokine therapies in response to systemic infection. J Invest Dermatol Proc 2001; 6:244-50.
13. Khraishi M. Comparative overview of safety of the biologics in rheumatoid arthritis. J Rheumatol Suppl 2009; 82:25-32.
14. Laiosa CV, Stadtfeld M, Graf T. Determinants of lymphoid-myeloid lineage diversification. Annu Rev Immunol 2006; 24:705-38.
15. Hamilton JA, Tak PP. The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases. Arthritis Rheum 2009; 60:1210-21.
16. Firestein GS, Zvaifler NJ. Anticytokine therapy in rheumatoid arthritis. N Engl J Med 1997; 337:195-7.
17. Pham TN, Brown BL, Dobson PR, Richardson VJ. Protein kinase C-eta (PKC-eta) is required for the development of inducible nitric oxide synthase (iNOS) positive phenotype in human monocytic cells. Nitric Oxide 2003; 9:123-34.
18. Barra L, Pope JE, Payne M. Real-world anti-tumour necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire. J Rheumatol 2009; 36:1421-8.
19. Ebert EC. Infliximab and the TNF-alpha system. Am J Physiol 2009; 296:G612-20.
20. Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 2009; 36:1118-25.
21. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
22. Granger DL, Taintor RR, Boockvar KS, Hibbs JB, Jr. Measurement of nitrate and nitrite in biological samples using nitrate reductase and Griess reaction. Methods Enzymol 1996; 268: 142-51.
23. Jungi TW, Thony M, Brcic M, Adler B, Pauli U, Peterhans E. Induction of nitric oxide synthase in bovine mononuclear phagocytes is differentiation stage-dependent. Immunobiology 1996; 195:385-400.
24. Dijkstra G, Zandvoort AJ, Kobold AC, et al. Increased expression of inducible nitric oxide synthase in circulating monocytes from patients with active inflammatory bowel disease. Scand J Gastroenterol 2002; 37:546-54.
25. Yamamoto T, Katayama I, Nishioka K. Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis. J Rheumatol 1998; 25:314-17.
26. Borderie D, Hilliquin P, Hernvann A, Kahan A, Menkes CJ, Ekindjian OG. Nitric oxide synthase is expressed in the lymphomononuclear cells of synovial fluid in patients with rheumatoid arthritis. J Rheumatol 1999; 26:2083-8.
27. Bergholm R, Leirisalo-Repo M, Vehkavaara S, Makimattila S, Taskinen MR, Yki-Jarvinen H. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol 2002; 22:1637-41.